SMAD2 and myelodysplastic syndrome: In addition, Galunisertib, an ALK5 inhibitor, was found to inhibit TGF-β-mediated SMAD2/3 hyperactivation and to stimulate hematopoiesis in bone marrow cells from MDS patients [15].